I see in 2 years their revenue has increased 126% and their bottom line has improved by 52%. What factor(s) have driven those #'s? Seems pretty impressive results to me at this point of my knowledge base of this company. I trade technicals first but they must be supported by a solid company. And at this point regardless of the last 3 days of price action, these charts are just very much ready for decent news Monday.
Also, you may want to check NASDAQ under detailed holdings of institutional ownership. Yahoo and Google via MSN only list the top 15 and the list does not show updated new positions. GS started a new 12/31/10 but it is unclear rather or not it is accumulating more shares while trying to stay under the radar of small investors.
Here is part of the report from Business Wire. I think most institutional investors are accumulating shares based on the future financial outlook of the company. Most may be looking forward to 2012 while placing less weight on current revenue levels (which have trended positive leading up to this point).
[Fourth Quarter and Year End 2010 Financial Results
Total revenue was $3.3 million and $12.8 million for the three months and year ended December 31, 2010, respectively, compared to $2.6 million and $8.3 million for the comparable periods in 2009, respectively. Product revenue increased in the fourth quarter to $1.6 million compared to $0.6 million in the prior year, and increased in the full year by 65% to $5.8 million compared to $3.5 million in 2009. The product revenue increase for the year was due primarily to a combination of the first full year of sales to Teva in connection with the launch of our Tjet needle-free device with their hGH Tev-Tropin® and an increase in sales to Ferring.
Licensing and development revenue decreased in the fourth quarter to $0.8 million compared to $1.7 million in the prior year, and increased in the full year to $5.0 million from $4.2 million in the prior year. Revenue for the quarter and full year periods of 2010 was primarily related to auto injector development work for the epinephrine product under our agreement with Teva along with revenue recognized under our agreement with Ferring. The decrease in the quarter was primarily due to timing of revenue recognized under the Teva agreement. The increase for the year was primarily due to revenue recognized under the Ferring agreement.
Revenue from royalties was $0.8 million and $2.1 million for the three months and year ended December 31, 2010, respectively, compared to $0.3 million and $0.6 million for the comparable period in 2009, respectively. The increase in royalties in the quarter and year-to-date periods was primarily due to royalties received from Teva on sales of their hGH Tev-Tropin®.
Total gross profit increased in the fourth quarter of 2010 to $2.4 million compared to $1.0 million in 2009, and increased for the year to $8.5 million in 2010 compared to $4.2 million in 2009. The increase in the quarter was primarily due to increases in product sales and royalties, which have higher gross margins than our other revenues. The increase for the year was due to increases in product sales and royalties as well as recognition of licensing fees under the license agreement with Ferring for which there were minimal direct costs.
Total operating expenses were approximately $3.6 million and $3.5 million for the fourth quarters of 2010 and 2009, respectively, and approximately $14.6 million and $13.9 million for the years ended December 31, 2010 and 2009, respectively. The increases in each period were primarily due to our Vibex™ MTX development program and other internally funded development projects. Fourth quarter research and development expenses were reduced by approximately $430,000 received from the qualifying therapeutic discovery grant program under section 48D of the internal revenue code. Research and development expenses in connection with the Phase III study of Anturol® for the treatment of overactive bladder was approximately $4.9 million in 2010 compared to $5.2 million in 2009.] Source: Business Wire for information
The company also gained about $5.1 million from exercised warrants and options in the first quarter of 2011.
To make it even simpler for you, the answer to your specific questions you can skip right to Item 6 of the 10K, which provides a good overview of all sources of revenue (product sales, development revenue, royalties) as well as expenses, and why certain items have changed over the period from 2008-2010. HOP
It's cool Koufax. Just the negative attitudes going around are getting tiresome. Particularly for a board that is supposed to be sounding intelligible arguments and evidence.
bent: Just my recommendation. First, read (or at least skim thru) the 10K from March. They make it really easy for folks nowadays. There's a link to it right from this AIS stock board. Why rely on 2nd hand account to answer your question, and risk getting incorrect info? Then if you need clarifications/elaborations, ask your questions on this message board. But do your homework first. No free lunches. HOP
Welcome to the land of Antares Message Board, a.k.a dreamers, weepers, longs, shorts and traders.
I only consider myself knowledgeable due to the fact that I have watched this company for more than 8 years. Other than that, I am still learning to go with the flow and dream of what might be.
For any new owners to the land of Antares, I truly hope that your wait is not as long as mine has been.
Some believe that Antares is due to breakout and rise in PPS within the next 6 months. if they are correct, your timing is perfect.
Good Luck & Enjoy the Show,